MPFS Final Rule Decreases Conversion Factor for 2027
CMS finalized the 2027 Medicare Physician Fee Schedule, including conversion factor reductions and QPP policy updates.
Read moreCMS released the 2027 Medicare Advantage and Part D Final Rule April 2, that will take effect Jan. 1. The final rule, eliminates the prescription drug coverage gap, lowers the annual beneficiary out of pocket cap, ends cost sharing in the catastrophic phase, and formally implements the Medicare Part D Manufacturer Discount Program. ACR® created a summary of relevant policies, including changes to the Star Ratings program and outlines changes that result from an executive order issued by the White House aimed to reduce duplicative and burdensome regulatory requirements (E.O. 14192).
CMS released the 2027 Medicare Advantage and Part D Rate Announcement April 6. The notice sets how much CMS will pay plans and finalizes proposals from an Advance Notice released in January.
The rate announcement updates benchmarks, capitation rates, risk adjustment models, coding patterns and payment impacts from 2026 Star Ratings. The Star Ratings program is a CMS system that rates MA and Part D plans from 1 to 5 stars based on quality, performance, and member experience to help beneficiaries compare plans and to determine bonus payments to plans. CMS projects a net average payment increase of 2.48%, or more than $13 billion in additional Medicare Advantage payments in 2027.
For more information or if you have questions, contact Kimberly Greck, ACR Senior Economic Policy Analyst.
MPFS Final Rule Decreases Conversion Factor for 2027
CMS finalized the 2027 Medicare Physician Fee Schedule, including conversion factor reductions and QPP policy updates.
Read moreCMS Finalizes Site-Neutral Payments for Non-Contrast Imaging Services in OPPS
ACR outlines key OPPS changes, including site-neutral payments for certain non-contrast imaging services beginning Jan. 1, 2027.
Read moreACR Applauds NRC for Adding IR to Medical Advisory Committee
ACR welcomes a new IR seat on the NRC advisory committee, strengthening expertise for radionuclide therapy, licensing and patient care.
Read more